EYES Average Annual Return 10 Years
Growth of $10,000.00
Without Dividends Reinvested Into EYES

Also see:
EYES stock yearly return 2014
EYES stock yearly return 2015
EYES stock yearly return 2016
EYES stock yearly return 2017
EYES stock yearly return 2018
EYES stock yearly return 2019
EYES stock yearly return 2020
EYES stock yearly return 2021
EYES YTD return
Compare EYES average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
Start date: 11/21/2014
End date: 08/30/2022
Start price/share: $507.36
End price/share: $4.14
Dividends collected/share: $0.00
Total return: -99.18%
EYES Average Annual Return: -46.12%
Starting investment: $10,000.00
Ending investment: $81.61
Years: 7.78

EYES average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
Second Sight Medical Products develops, manufactures and markets implantable visual prosthetics that deliver artificial vision to blind individuals. Co. is developing the Orion® Visual Cortical Prosthesis System, an implanted cortical stimulation device which provides artificial vision to individuals who are blind due to a range of causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease and eye injury. Co.'s commercially approved product, the Argus® II Retinal Prosthesis System, treats outer retinal degenerations, such as retinitis pigmentosa, a hereditary disease that causes a progressive degeneration of the light-sensitive cells of the retina. The EYES average annual return since 2014 is shown above.

The Average Annual Return on the EYES average annual return since 2014 page and across the coverage universe of our site, is a measure of the annualized return over the past ten years (or specified start date) for a given investment (up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window to capture long-term trends.

Thus, researching Average Annual Returns is good practice for investors — whether EYES average annual return since 2014 or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors by performing the EYES average annual return calculation with any dividends reinvested as applicable (on ex-dates).
Quotes delayed 20 minutes

Email EnvelopeFree EYES Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Second Sight Medical Products (EYES) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

EYPT Average Annual Return
FATE Average Annual Return
FBIO Average Annual Return
FBRX Average Annual Return
FDMT Average Annual Return
FEMY Average Annual Return
FGEN Average Annual Return
FHTX Average Annual Return
FIXX Average Annual Return
FLGT Average Annual Return
More Healthcare companies »


EYES Average Annual Return 10 Years | www.AverageAnnualReturn.com | Copyright © 2021 - 2022, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.